Thymosin Alpha-1: Benefits, Dosage & FDA Status
Thymosin Alpha-1 (Tα1)
A 28-amino-acid thymic peptide that matures and modulates T-cells. Used internationally as an adjunct in hepatitis, sepsis, and immune-compromised cancer care.
FDA Status
Approved in 35+ countries for hepatitis B/C, immune support; not FDA-approved in US (orphan-drug designations)
Typical Dose
1.6 mg twice weekly (subcutaneous)
Evidence Grade
AStrong RCT or FDA-approved evidence
Half-Life
~2 hours
Routes of Administration
subcutaneous
First Synthesized
1977
Clinics Indexed
192 providers have offered Thymosin Alpha-1 in our tracked directory.
Mechanism of Action
Activates Toll-like receptor 9; promotes maturation of naïve T-cells and modulates dendritic-cell function.
Key Reported Benefits
- ✓T-cell maturation
- ✓Antiviral immunity
- ✓Tumor immune support
- ✓Sepsis adjunct
Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade A indicates strong rct or fda-approved evidence.
Reported Side Effects
- •Injection-site reactions
- •Mild flu-like symptoms (initial doses)
Contraindications
- ⚠Active organ transplant on immunosuppression
Commonly Stacked With
Regulatory & Safety Context
FDA status: Approved in 35+ countries for hepatitis B/C, immune support; not FDA-approved in US (orphan-drug designations)
This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.
See state-by-state legality: US peptide legality by state →
References
Selected primary literature on Thymosin Alpha-1. Full PubMed records linked. Additional citations are available on request.
Last reviewed: 2026-04-30
Related Peptides
LL-37
BThe only human cathelicidin antimicrobial peptide. Active against bacteria, viruses, and biofilms. Investigated topically for infected wounds and mucosal infections.
TB-500
BA synthetic fragment of thymosin beta-4 that promotes cell migration, blood vessel formation, and tissue repair. Often stacked with BPC-157 as the 'Wolverine Stack.'
KPV
C+The C-terminal tripeptide of α-MSH with documented anti-inflammatory activity in IBD and dermatitis preclinical models. Frequently delivered orally and topically.
ARA-290
BAn 11-amino-acid peptide derived from the helix-B region of erythropoietin. Activates the tissue-protective receptor without erythropoietic side effects. Investigated for neuropathy and inflammation.
VIP
BA 28-amino-acid neuropeptide with broad immunomodulatory effects. Used clinically (intranasal) by some practitioners for chronic inflammatory response syndrome (CIRS).
PDA
C+A 15-amino-acid arginate analog developed as a more stable, sometimes more bioavailable alternative to BPC-157. Limited published research; popular among compounding pharmacies in 2025–2026.